What side effects are associated with this type of intervention?

Common treatments for Obsessive-Compulsive Disorder (OCD) include medications like fluvoxamine, acamprosate, agomelatine, memantine, saffron, D-cycloserine, duloxetine, crocin, and valerian root extract. Known side effects of these treatments can vary. For instance, fluvoxamine may cause nausea, insomnia, decreased motivation, and sedation. Agomelatine can lead to nausea, headache, dizziness, and somnolence. Duloxetine is associated with dry mouth, constipation, fatigue, and decreased appetite. Valerian root extract may cause somnolence. While celecoxib, an anti-inflammatory, is being studied for its potential benefits in OCD, its common side effects include gastrointestinal issues, cardiovascular risks, and potential kidney problems.

What prior FDA approvals exist?

The FDA has approved several medications for the treatment of Obsessive-Compulsive Disorder (OCD), primarily focusing on selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, fluvoxamine, and sertraline, as well as the tricyclic antidepressant clomipramine. These medications are primarily aimed at modulating serotonin levels to alleviate OCD symptoms. While anti-inflammatory treatments like Celecoxib are being studied for their potential benefits in OCD, they have not yet received FDA approval for this indication. Current research is exploring the role of neuroinflammation in OCD and whether anti-inflammatory medications can provide additional therapeutic benefits.

What other types of research exist?

As of 2024, promising novel alternatives to Celecoxib for treating Obsessive-Compulsive Disorder (OCD) include investigational drugs targeting neuroinflammation and other novel mechanisms. While specific new drugs are not detailed in the provided context, ongoing research into anti-inflammatory medications and other pharmacologic agents targeting different pathways in OCD may offer new treatment options. Patients should consult with their healthcare provider to discuss the latest available treatments and clinical trials.

← Back to Search

Celecoxib for Obsessive-Compulsive Disorder

Phase 2

Waitlist Available

Led By Jeffrey Miller, M.D.

Research Sponsored by New York State Psychiatric Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18 to 55 years old

Principal diagnosis of Obsessive-Compulsive Disorder (OCD)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 8

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if adding the anti-inflammatory drug celecoxib to current treatments helps adults with OCD who still have symptoms. It focuses on patients with high brain inflammation, measured by scans and blood tests, to see if they improve more with this added medication. Celecoxib has been tested as an additional therapy in schizophrenia, showing significant improvement in symptoms, particularly in patients with recent-onset schizophrenia.

Who is the study for?

This trial is for adults aged 18-55 with Obsessive-Compulsive Disorder (OCD) who still have symptoms despite current medication. Participants must be able to consent and not have medical conditions or metal implants that could interfere with brain scans, nor take medications like antipsychotics or steroids that affect the study drug.

What is being tested?

The study tests if celecoxib, an anti-inflammatory medicine, can help people with OCD when added to their existing treatment. It involves measuring inflammation in the brain and blood to see if these can predict the benefit from celecoxib.

What are the potential side effects?

Celecoxib may cause digestive issues like stomach pain and heartburn, kidney problems, swelling in legs or arms due to fluid retention, increased risk of heart attack or stroke, and allergic reactions such as rash.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

Select...

My main diagnosis is Obsessive-Compulsive Disorder.

Select...

My OCD symptoms persist despite taking psychiatric medication.

Select...

I am between 18 and 55 years old.

Select...

I understand and can agree to the study's procedures and risks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Yale-Brown Obsessive Compulsive Scale

Secondary study objectives

CRP

MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel

PGE2

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Celecoxib TreatmentExperimental Treatment1 Intervention

Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Celecoxib

2019

Completed Phase 4

~1740

0 / 5Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Obsessive-Compulsive Disorder (OCD) include selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). SSRIs increase serotonin levels in the brain, which helps alleviate OCD symptoms by improving mood and reducing anxiety. CBT, especially exposure and response prevention (ERP), helps patients face their fears and reduce compulsive behaviors. Additionally, anti-inflammatory medications like celecoxib are being studied for their potential to reduce neuroinflammation, which may contribute to OCD symptoms. Understanding these mechanisms is important for developing effective treatment plans tailored to individual patient needs.